Current Report Filing (8-k)
26 July 2017 - 7:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________________
FORM
8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 24, 2017
_______________________________
PEREGRINE
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-32839
|
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
14282 Franklin Avenue, Tustin, California 92780
|
(Address of Principal Executive Offices)
|
|
|
|
|
|
Registrant’s telephone number, including area code:
(714) 508-6000
|
|
Not Applicable
|
(Former name or former address, if changed since last report)
_______________________________
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
On July 24, 2017, Peregrine
Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Office of General Counsel notifying the Company
that it has regained compliance with the $1.00 minimum closing bid price requirement set forth in the NASDAQ Listing Rule 5550(a)(2),
and is in compliance with other applicable requirements for listing on The Nasdaq Stock Market. Accordingly, the NASDAQ has determined
to continue the listing of the Company’s securities on The Nasdaq Stock Market and considers the matter closed.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: July 25, 2017
|
PEREGRINE PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Paul J. Lytle
|
|
|
Paul J. Lytle
Chief Financial Officer
|
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2024 to May 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From May 2023 to May 2024